This common liver supplement could boost cancer treatment success

Salk Institute scientists discovered that bile acids in the liver can weaken immune cell function, making immunotherapy less effective against liver cancer. They pinpointed specific bile acids that suppress T cells and found that supplementing with UDCA reversed the effect, controlling tumor growth in mice. Since UDCA is already used for liver disease, it could quickly translate into clinical trials.